Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 10;14:740. doi: 10.1038/s41467-023-35943-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a The data (dots) and fitted curve (red line) from¹⁷ that translates neutralisation level (relative to that for convalescent) to the degree of protection against symptomatic disease. b The steps needed to scale efficacy for a 12-week dose interval to that for a short 3- or 4-week dose interval: (steps A, B) 12-week efficacy is translated to a relative neutralisation level via the red curve¹⁷; (step C) neutralisation level is reduced according to the values obtained by the Com-COV study ¹⁸; (steps D-E) the reduced neutralisation level is translated to a reduced efficacy for the shorter dose interval. c The consequences of this process for the AstraZeneca (AZ) and Pfizer (PF) vaccines against the Alpha and Delta variants, and hence the modified vaccine efficacy estimates for model (iv).